| General Information of Drug (ID:
DR5973) |
| Drug Name |
Anifrolumab
|
| Synonyms |
. |
| Indication |
Lupus erythematosus
[ICD11: 4A40]
|
Phase 3
|
[1]
|
|
|
|
|
|
|
|
| The Metabolic Roadmap of This Drug |
|
|
| The Full List of Drug Metabolites (DM) of This Drug |
| DM Name |
DM ID |
PubChem ID |
Reaction |
DM Level |
REF |
|
Amino acids
|
DM004985
|
N. A. |
Unclear |
1 |
[2]
|
|
Smaller oligopeptides
|
DM004984
|
N. A. |
Unclear |
1 |
[2]
|
|
|
|
|
|
|
|
| The Full List of Metabolic Reaction (MR) of This Drug |
|
|
|
|
|
|
|
|
| References |
| 1 |
ClinicalTrials.gov (NCT02794285) Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus (TULIP SLE LTE). U.S. National Institutes of Health.
|
| 2 |
Pharmacokinetics of Monoclonal Antibodies
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
